-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CeuOiXAy9ahy7v7/ZBiDPgqV2wCNlZwZOdIyqkjPe/bhdMGE1auJ+0IAkSoC/8IB
 0/j5OM+dtf8ZrgcxFDR6uQ==

<SEC-DOCUMENT>0001193125-09-048669.txt : 20090309
<SEC-HEADER>0001193125-09-048669.hdr.sgml : 20090309
<ACCEPTANCE-DATETIME>20090309172504
ACCESSION NUMBER:		0001193125-09-048669
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090303
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090309
DATE AS OF CHANGE:		20090309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NATURAL ALTERNATIVES INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000787253
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				841007839
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15701
		FILM NUMBER:		09667099

	BUSINESS ADDRESS:	
		STREET 1:		1185 LINDA VISTA DR
		CITY:			SAN MARCOS
		STATE:			CA
		ZIP:			92069
		BUSINESS PHONE:		6197447340

	MAIL ADDRESS:	
		STREET 1:		1185 LINDA VISTA DRIVE
		CITY:			SAN MARCOS
		STATE:			CA
		ZIP:			92069

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERICAN ACQUISITIONS INC
		DATE OF NAME CHANGE:	19860929
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>of the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>DATE OF REPORT (Date of earliest event reported): MARCH 3, 2009 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>000-15701 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission file number) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>NATURAL ALTERNATIVES
INTERNATIONAL, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>84-1007839</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State of incorporation)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer Identification No.)</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>1185 Linda Vista Drive</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>San Marcos, California 92078</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>(760) 744-7340</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number)</B></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;1.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Entry into a Material Definitive Agreement. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT
FACE="Times New Roman" SIZE="2">On March&nbsp;3, 2009, Natural Alternatives International, Inc. (&#147;NAI&#148;) entered into an Agreement to Sublicense with Compound Solutions, Inc. (&#147;CSI&#148;) under which NAI has agreed to grant a
sublicense of certain of its rights under that certain License Agreement effective as of April&nbsp;28, 1997, by and among NAI, Roger Harris and Mark Dunnett, as amended (the &#147;License Agreement&#148;), to customers of CSI who purchase the
material beta-alanine from CSI (the &#147;CSI Agreement&#148;). The sublicense will allow CSI&#146;s customers to manufacture, offer for sale and/or sell products incorporating, using or made in accordance with certain patent rights licensed to NAI
under the License Agreement and certain trademark rights of NAI in the mark Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>. NAI will receive a sublicense fee from CSI that will vary based on the amount of net sales of
beta-alanine sold by CSI and CSI&#146;s related costs. A copy of the License Agreement was previously filed with the United States Securities and Exchange Commission as Exhibit 10.22 of NAI&#146;s Annual Report on Form 10-K for the fiscal year ended
June&nbsp;30, 2005, filed with the commission on September&nbsp;8, 2005. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">On March&nbsp;9, 2009, NAI issued a press release
announcing the CSI Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibits. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Press release dated March&nbsp;9, 2009 of NAI. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Natural Alternatives International, Inc.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date: <B>March&nbsp;9, 2009</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/&nbsp;&nbsp;&nbsp;&nbsp;Ken Wolf</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Ken Wolf</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2"><B>Chief Financial Officer</B></FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g90682g91a98.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:10px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Natural Alternatives International, Inc. </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Announces Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> Beta-Alanine
Licensing Agreement </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2"><B>SAN MARCOS, Calif.</B>, March&nbsp;9/PRNewswire-FirstCall/ &#151;
Natural Alternatives International, Inc. (&#147;NAI&#148;) (Nasdaq: NAII), a leading formulator and manufacturer of customized nutritional supplements, and Compound Solutions, Inc. (&#147;CSI&#148;), a science and marketing based distributor of raw
materials to the sports nutrition, dietary supplement, food, pharmaceutical and personal care industries, today jointly announced their licensing agreement of the patented Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>
beta-alanine to further develop its use in the dynamic human performance product market. CSI is an importer and distributor of bulk beta-alanine. Under the license agreement, CSI&#146;s customers will receive a sublicense of certain of NAI&#146;s
rights to the use, manufacture and sale of products incorporating the patented Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> beta-alanine. CSI will continue to work with manufacturers of human performance products to drive
sales of products with the addition of Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> beta-alanine.&nbsp;NAI also plans to focus on the development and production of all types of dosage form products using Carnosyn<FONT
FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>.&nbsp;Tablets, two piece capsules and powders in many types of packaging are expected to be formulated and manufactured at NAI&#146;s certified manufacturing facilities in both Vista, CA and
Lugano, Switzerland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">Barry Titlow, Chief Executive Officer of CSI, stated: &#147;We are very
excited about our relationship with NAI.&nbsp;We believe the science behind Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> is so well documented our clients will be able to reference the studies with total confidence.&nbsp;We
intend to continue to ensure superior quality of the bulk beta-alanine and the continuity of the supply chain.&nbsp;We are inspired by the products now on the market that contain Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT>
and look forward to the future development of this market.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">Mark LeDoux, Chief Executive
Officer of NAI added: &#147;We are very pleased to announce this affiliation because of our longstanding relationship with Barry Titlow and CSI.&nbsp;We plan to aggressively defend our patent estate associated with Carnosyn<FONT
FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> beta-alanine, which we believe is based on unsurpassed scientific and intellectual effort and represents a dynamic estate of intellectual property deserving of commercialization without
interference.&nbsp;We believe Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> beta-alanine is truly a breakthrough in performance nutrition.&nbsp;It lends itself well to presentations to consumers in capsule, tablet and
compounded form with all sorts of supplement ingredients.&nbsp;We believe there is a large and growing marketplace for Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> beta-alanine and are ready to assist those willing to use
the benefits of the patent estate in a lawful manner.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">The recognition of beta-alanine by athletes of all levels has been
underscored by increasing sales of performance products containing Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> beta-alanine.&nbsp;Controlled studies have demonstrated that carnosine is a highly effective buffer to slow the
acidic buildup in exercise stressed muscle, which otherwise could lead to shortened workouts and non-optimal competitive performance. Carnosine synthesis in the body is limited by the availability of beta-alanine.&nbsp;As confirmed in multiple
studies, orally delivered Carnosyn<FONT FACE="Times New Roman" SIZE="1"><SUP>&reg;</SUP></FONT> beta-alanine increases muscle tissue levels of carnosine, to provide cellular buffering for significant performance and recovery improvement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">CSI is a unique science and marketing based distributor of fine chemicals known for its concept development and global scope.&nbsp;CSI provides raw materials from
highly qualified manufacturers to the sports nutrition, dietary supplement, food, pharmaceutical and personal care industries.&nbsp;CSI is involved from concept presentation, to process and dosage improvements, to marketing programs for its clients.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic
partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients,
customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information
about NAI, please see our website at http://www.nai-online.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">This press release contains forward-looking statements within the meaning of
Section&nbsp;21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and
beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, and our ability, as well as that of CSI, to further develop, commercialize, market, sell
and manufacture Carnosyn beta-alanine, to successfully defend our intellectual property rights in Carnosyn beta-alanine, and to maintain the quality and continuity of the supply of beta-alanine, as well as future market conditions related to and
acceptance of Carnosyn beta-alanine, economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods
to differ </FONT>
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are
further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">SOURCE - Natural Alternatives International, Inc. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">CONTACT
&#150; Kenneth Wolf, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or<BR> <U>investor@nai-online.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Web site:
<U>http://www.nai-online.com</U> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g90682g91a98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g90682g91a98.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!X17AI9@``24DJ``@````&`#$!`@`1
M````5@````$#!0`!````:`````,#`0`!`````LI(`A!1`0`!`````0#__Q%1
M!``!````Q`X``!)1!``!````Q`X```````!-:6-R;W-O9G0@3V9F:6-E`/^@
MA@$`C[$``/_;`$,`"`8&!P8%"`<'!PD)"`H,%`T,"PL,&1(3#Q0=&A\>'1H<
M'"`D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_;`$,!"0D)#`L,&`T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_``!$(`'\`;0,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0``
M`````````0(#!`4&!P@)"@O_Q`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%
M$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U
M-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*
MDI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:
MX>+CY.7FY^CIZO'R\_3U]O?X^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#
M!`4&!P@)"@O_Q`"U$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q
M$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?H
MZ>KR\_3U]O?X^?K_V@`,`P$``A$#$0`_`/?Z***`"BBB@#A];@U;0M6NKW3;
MN.WL[O$DC3\QQ2="3UZ\?E6;9>(_$=GX@B75+JVELIDW1R*`B/CJH)XZ8.>.
M_6O2'19$*.H96&"K#((KE==\)V$D<UTGV:$'#,MPFY`P/!&3\IYQT/TIG92K
M0DN6:\KV,F7XD[V)MXK;8L;/DNSA\9'!`&!D8[^M)JOCF[N]%E;3%BAO5<QK
M$)0[E_X4QP>>N?3O4*7>S3-=:1$:6.")/]5M1%R1A`5!`PWYU:L=(A\0W@FD
MDMEDB7:IE@S/CIDG"\CID9%!MR4H^\X[%--1\73+]A?4K:2Z=0IA@7;,@.,L
M>.,9]>U=[I&G+I.DV]BK;_*7!;U/<_G3['3;3381%:PA`!@MU8_4U;I')5JJ
M>D59!11108!1110`444UW$:,[<*H)-#=M6`K,J(68@*!DD]J@>^MH[/[695\
MG&0P[_2LN]N9]3\/L]M`X:1MNT<DKGFG6;/>K%;3Z44@C7[TC<`CVKSI8YRJ
M<E/JDT[.S;]%LNILJ5E>7<ET[6AJ<[)#;2"->LC$8J#Q'&Y6WFZ0QAR6(R$?
M`VL?3'S<]LULQ0QPILBC5%]%&*JZO'-+I5Q';E_,9<#8<$C/('X9KKP\*L(6
MJRYI>EA*4?:)Q5D<9JDUH=*NOL5C*$F@&]D7>&8,#U'WLC//M5ZR>&?4K7^S
M[<QQ;HW5%ZJ/XV/]T$<8/6N6\1V$$]S%J=A<7=N;1\)]B^4%2Z#8X'*D#<26
MX]Z[[0-TLDEP@3RWC42R1_<EE[LOJ,<9[UN==2T:=T:UW.UM;/,D+2[>2JGG
M%4],UNVU)C&H,<HYV-WK3JA=6T=NOVFWL$EG4Y`7"GZUQUU6C-5(2]U;JU_N
MMK<XX<K5FM2W'<12RR1)(K/&<.HZBI*Y^S>YGU_[4;.6"-H]DF>Y[&M2ROUO
M);B/84>!]I!/7T-3AL9&KI+1MM+1J]M>OD.=-QV+E%%%=ID%9S71OFU"RCC^
M:)-@.>I(JQ?WJ6%OYTBDKN"X'O6/<:;>?VC/-;W:6T%P5RQ/)^E>?C:\HM0I
MKF_F2WLT[;^9M2BGJ].P66F:LL$=NUXD,"?\\N6/MFNA[56L;..PM5@C+,`2
M2S'DD]35FM<'AE0II:WTW=[>1-6?.PILBL\3JK%6*D!AV/K3J*ZS,\FURR-M
MJ5N]Q9ZA;W-O*"'M<XFC,B#`Q]XG+''^U7?>&;>Z@T]FN(7@21MT4#GYD7W]
M">N*A\1:;<7U_I[Q)(4B<,2F/O!U(W9_AX/3FNAH.JK6YJ<4%%%%!RE#4+6]
MF=);.[,3*,%&&5:J=A;W=B]_>W81W==W[L\$@=*VZP+S2+B-Y187@C6?.Z&0
M\'/7%>7C*+A-5X1<FNB?6UD[/0WIRNN1NQKV5T+RSBN`NW>,X]*L5F64J6!L
M],93YK1;B1T&.M:==N&J.=-<S]Y6OZVU,YQL]-C-U-8M1MKFQ1QYZ*&V^G<5
MGV%A=7MQ$^HSJ?LX!6W4\J>Q(I^KQ75EJ":E9KO+#RY$ZY/05:T2S>".6XN'
M#W4S9D(.=OM7E2A[?&\M2+NM_P"5Q6L7YOR]3=/DI73_`,[]30N$DD@98I#&
M^.&`S6?IM[(UP]O.^\E=\;8QGL1^!K4/0UB7L+Q)%=0CYT.]?<CJ/Q'\J[<6
MY4Y1JQZ;KNO3^NAE3LTXLM:I]JBQ+!.RAL(%`Z,>AJ_$K)$JN^]@.6QC-0-,
MEQ:PS(<J[(P_.K5;4H+VDIIW32ZZ$R?NI%"_OFM+BU0#Y7?#GT'3^9%7ZQ-0
MB-R)Y`3A\Q+Z97D'\^*T[&X%U8PS=V49]CWK+#UY2KSC+;=?D_T?S*G%**:'
MSQ/*F(YFB/J!FL&XFU*)[95O.99O(;*#@^HKHZP+W_CYL_\`L(5EF,?=4DVG
MY-KJBJ+UL;<$;Q1[7E:0_P!XC%4M7L%O(%D67R9H?F27.`OU]JT:9+&LT3Q.
M,JX*D>U=E6A&I2=-JZ_KKN91DU+F,#3HKD7\NHZBZ[8HL*Z\JP]16_%*DT2R
M1MN1AD'UKE&MM2"C2(V$EK(QVR@Y^4=1FNKAC6&%(D^ZBA1^%>?E<I6E#E:2
MW;W<GOKU25M3?$):._\`PQSL]U=:%=7"E'FMYB6B8G.UCVK1T"W:#3LR,#+(
MY=P#T)[5236?*EEL]7B42*<JVWY6]*E\,[GM;FX;($LQ8`_Y]ZYL).'UN*A)
MM>]9/>'>_P"2+J)^S=UVU[FV>AJMY/GV.SH>JGT.>*GFD6*%G=@J@=3572[D
M7%F-Q`D0E77/0YKV)R@ZBIRZI_H<R3Y>9&;8RF"8V;<*T@DB![<_,OX&MNXD
M\FW>3N!Q]>U9FH6JB_MI>@,RL#Z-GD?B*GO[I%GM[<D8:0;SV`YP#]:XZ,I4
M(3A)[:+Y[?UV-))3::*7F:DMDL/]F'Y2&W>:O7.:L:,X0W-J#Q&^]/\`=;FM
M3(`R3Q7/)>06NMP`.NR56C//0`_+45(+"U*<Y3NMM;;;=$NK7W#B_:1:2.BK
M`O?^/FS_`.PA6\6`&20!ZUS=]=0">S8RKC[<7Z_P^M:9G**IJ[_JZ%03<CI:
M*J7MRT42F(KECC<>0/\`Z]16%W)=I(KG^$$'&",YX(KK>)@JGLNIGR/EYC#C
MO;C29+FQ@B,OFN6MRO(YZUOZ5:R6E@D<SEY3EG).>37/Z7JEMIMG*MRF;B*1
M@@Q\QS_*M_29KRXL_.O$",[$HH&,+VKQ\JG"4U[S;L[+I%7U3\[Z+R.G$)I/
M3Y]Q-1BT^<I!>>6'?A"W!_`U0U"1]*;3+>VD*Q[]K+_>&1_C6CJ.F0:E"$E!
M#+]UQU6L9-!OEOK4SW`GMXGR,GE1^/T%;8Z%?G?LZ>KM:2W6JO?J32<+>\]N
MG^1TC(LB[74,OH1FD2&*,YCC1"?[J@5CV]]/'XDGLII-T;KNC']WO6W7HT*T
M*]Y):Q;7W&$XN&G<:Z*X`900"",^HJ&:QMIV+2PJQ.,Y]JR]8N/)NF:]DN(K
M!(M^80<,>^YAT^G>N?E1+A!<V&E2-YN"&L9G61?3+_=K>5.$])*YI"FVKWL=
MRT,;1>45RF,8JE]@THS>5Y4!EQ]S/S?E7GUQK^K6,GV6[O9-H?`TZ[7;-*O3
M"S+\KUHOJVV+_2+"32-I_=!H2RC_`&C,N1^`S4SH4Y_%%/Y&OU><=GOV_K^N
MYW<EO#+$(G0,@Z`U7_LG3_\`GTC_`"KD+?Q#;?:_L]IKRW=TR[H%CE,N\C'R
M,I'&<\'V-=U&6:)"Z[7(!8>AI3H4IZRBG\C&<9T^I#]BMO(,/DKY9.2M96I2
M_P!GWMA!;'RUFE!D[EAD#DGZU=UJ]:QTR69#AS\JGW-9MUIUYJ.E:>X?==*<
MF1CC`/.?Y5YF/DK2I4(^^DGIVOM\]2Z2VE-Z?\`O3V>F6]\;NYV"65AM#],^
MPK4K#LO#^RX%S?SFYF!R`>@K<KKP49VE*5-0N]NOJS.JUHD[A6)J%AJ8O'NK
M"[/S=8G/`^G:MNBML1AXUX\LFUYIV9,)N#NCE[.TU-];AN[V`\#!9<<<<58L
M;F:S\0SV,TK.DIW1ECG'?_/TJSJ&GZC)=&XLKXQ@@`QMTK)%K=6VJ076H7T`
ME0@X=N2O^<UX$X3PLXJ,9:3NY-JS3T>OGYG6FJB=VMMC?LM3MM1:6*/(9"0R
M..2*:-%LE!5!-&G9(YW51]`#@5S][>6UOX@AN[.92K$>;MZ>]=:98U*@NH+=
M,GK7JX#&^VYX3:;B[76S71F-2#A9QT3*XTNP%N\'V.`Q2??5D!#_`%SU_&J'
M_"+:;&X:V%Q:X/"6]PZ(/^`@[?TK:IK.J8W,!GIDUZ+=C)3DMF4+;3K+2%FN
M07+$9DFFD+MCTR>@]A56[UV-M&ENK8,"6\M-PQSZU6\571"06BN%#G<_T[?U
MJ/4!976FVUI:7EO&L9R=YQDXKPL;CZG/5I4FERKYMOMZ'3"G=1G/6_Y#I]/N
M[CPU!&-\\[N).3T!^M$=IK]Q&L#RK;PJ`O&,X_#FECTS79$$;WX2/U![?A71
M0H8H41G+E0`6/4U&'P2KRYI*<$DEO:]O34)U>165GJ-MH3!;1Q-(TA10"S=3
M4M%%>_&*BE%=#D;OJ%%%%,053O-+L[]E:XA#,HP""0<?A5RBHJ4X5(\LTFO,
M:DXNZ,V/0["V#-#:HSXX$A)&?QKFKRSOX)9;R]3[H^0@Y4'MCVKMZAN;:&[B
M\J=`Z9!P:\S&952K4[4O=:V2T5_/0WIXB47>6IQ#ZG?V\<`2ZDPR>9R<Y))_
MPITBSWUV]N6>21DWQ@G.TXSBNFU#0X+Z:V8`(L9PP`QE?2KOV&V^TI<B)1*@
MP&'I7F1R;$RDX5)WBFNNZMK8W>)@E=+4R=+TV:6T:+5+9'"\1LW+`>F:M)X=
MTQ'#"WR1ZN2*U**]NGEV'C!1E%2:ZM)LY95IMMIV```8'04445W&04444`?_
!V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
